InvestorsHub Logo
Followers 14
Posts 730
Boards Moderated 0
Alias Born 12/09/2013

Re: None

Thursday, 11/17/2016 9:14:26 AM

Thursday, November 17, 2016 9:14:26 AM

Post# of 2930
Late breaker presentation 2nd gen G/P
8 weeks treatment Genotype 2, 4, 5, or 6


http://www.natap.org/2016/AASLD/AASLD_40.htm

SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News